Senseonics Holdings, Inc., a company developing the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Health Care Service Corporation (HCSC) – Blue Cross Blue Shield is now providing coverage for the Eversense CGM System.
The expanded coverage became effective on October 15, 2019.
This decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.
Health Care Service Corporation, a Mutual Legal Reserve Company (HCSC), and an Independent Licensee of the Blue Cross and Blue Shield Association is the fourth-largest health insurer in the U.S. operating as Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma, and Texas.
HCSC serves more than 16 million members across five states.
“Having HCSC recognize Eversense as one of their covered diabetes management tools demonstrates that more payers are seeing the value that our long-term CGM brings to their members with diabetes,” said Dr. Tim Goodnow, president, and chief executive officer of Senseonics.
Goodnow said increasing patient access for Eversense has been a top corporate priority and this is a significant milestone in helping the company reach approximately 100 million covered lives on the path to widespread insurance coverage.
With each new coverage decision, we are able to reduce the financial barriers and help millions of people with diabetes experience the freedom that Eversense brings for up to 90 days of continuous glucose readings.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends, and alerts.
In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts when high or low glucose thresholds are crossed and can be removed, recharged and re-adhered without discarding the sensor.
The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).
Feature image courtesy: Senseonics Holdings, Inc.
Senseonics Holdings, Inc. (2019, October 14). Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation – Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma, and Texas. Business Wire. Retrieved October 21, 2019, from https://www.businesswire.com/news/home/20191014005667/en